Literature DB >> 24707903

Investigating the role of nucleotide-binding oligomerization domain-like receptors in bacterial lung infection.

Mary Leissinger1, Ritwij Kulkarni, Rachel L Zemans, Gregory P Downey, Samithamby Jeyaseelan.   

Abstract

Lower respiratory tract infections (LRTIs) are a persistent and pervasive public health problem worldwide. Pneumonia and other LRTIs will be among the leading causes of death in adults, and pneumonia is the single largest cause of death in children. LRTIs are also an important cause of acute lung injury and acute exacerbations of chronic obstructive pulmonary disease. Because innate immunity is the first line of defense against pathogens, understanding the role of innate immunity in the pulmonary system is of paramount importance. Pattern recognition molecules (PRMs) that recognize microbial-associated molecular patterns are an integral component of the innate immune system and are located in both cell membranes and cytosol. Toll-like receptors and nucleotide-binding oligomerization domain-like receptors (NLRs) are the major sensors at the forefront of pathogen recognition. Although Toll-like receptors have been extensively studied in host immunity, NLRs have diverse and important roles in immune and inflammatory responses, ranging from antimicrobial properties to adaptive immune responses. The lung contains NLR-expressing immune cells such as leukocytes and nonimmune cells such as epithelial cells that are in constant and close contact with invading microbes. This pulmonary perspective addresses our current understanding of the structure and function of NLR family members, highlighting advances and gaps in knowledge, with a specific focus on immune responses in the respiratory tract during bacterial infection. Further advances in exploring cellular and molecular responses to bacterial pathogens are critical to develop improved strategies to treat and prevent devastating infectious diseases of the lung.

Entities:  

Keywords:  bacterial infection; inflammasome; lung; nucleotide-binding oligomerization domain–like receptors

Mesh:

Substances:

Year:  2014        PMID: 24707903      PMCID: PMC4226013          DOI: 10.1164/rccm.201311-2103PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  66 in total

Review 1.  Molecular mechanism of NLRP3 inflammasome activation.

Authors:  Chengcheng Jin; Richard A Flavell
Journal:  J Clin Immunol       Date:  2010-06-30       Impact factor: 8.317

2.  Ventilator-induced lung injury is mediated by the NLRP3 inflammasome.

Authors:  Maria T Kuipers; Hamid Aslami; John R Janczy; Koenraad F van der Sluijs; Alexander P J Vlaar; Esther K Wolthuis; Goda Choi; Joris J T H Roelofs; Richard A Flavell; Fayyaz S Sutterwala; Paul Bresser; Jaklien C Leemans; Tom van der Poll; Marcus J Schultz; Catharina W Wieland
Journal:  Anesthesiology       Date:  2012-05       Impact factor: 7.892

3.  Innate immune detection of bacterial virulence factors via the NLRC4 inflammasome.

Authors:  Edward A Miao; Sarah E Warren
Journal:  J Clin Immunol       Date:  2010-03-27       Impact factor: 8.317

4.  K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter.

Authors:  Raúl Muñoz-Planillo; Peter Kuffa; Giovanny Martínez-Colón; Brenna L Smith; Thekkelnaycke M Rajendiran; Gabriel Núñez
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

5.  Genomic sequence analysis of the mouse Naip gene array.

Authors:  M G Endrizzi; V Hadinoto; J D Growney; W Miller; W F Dietrich
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

6.  NLRC4 inflammasome-mediated production of IL-1β modulates mucosal immunity in the lung against gram-negative bacterial infection.

Authors:  Shanshan Cai; Sanjay Batra; Nobuko Wakamatsu; Pal Pacher; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2012-04-30       Impact factor: 5.422

7.  Flagellar motility is a key determinant of the magnitude of the inflammasome response to Pseudomonas aeruginosa.

Authors:  Yash R Patankar; Rustin R Lovewell; Matthew E Poynter; Jeevan Jyot; Barbara I Kazmierczak; Brent Berwin
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

8.  Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria.

Authors:  Edward A Miao; Irina A Leaf; Piper M Treuting; Dat P Mao; Monica Dors; Anasuya Sarkar; Sarah E Warren; Mark D Wewers; Alan Aderem
Journal:  Nat Immunol       Date:  2010-11-07       Impact factor: 25.606

9.  NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis.

Authors:  Gerben Ferwerda; Stephen E Girardin; Bart-Jan Kullberg; Lionel Le Bourhis; Dirk J de Jong; Dennis M L Langenberg; Reinout van Crevel; Gosse J Adema; Tom H M Ottenhoff; Jos W M Van der Meer; Mihai G Netea
Journal:  PLoS Pathog       Date:  2005-11-25       Impact factor: 6.823

10.  Nucleotide-binding oligomerization domain containing-like receptor family, caspase recruitment domain (CARD) containing 4 (NLRC4) regulates intrapulmonary replication of aerosolized Legionella pneumophila.

Authors:  William R Berrington; Kelly D Smith; Shawn J Skerrett; Thomas R Hawn
Journal:  BMC Infect Dis       Date:  2013-08-10       Impact factor: 3.090

View more
  13 in total

Review 1.  The NLRP6 inflammasome in health and disease.

Authors:  Laxman Ghimire; Sagar Paudel; Liliang Jin; Samithamby Jeyaseelan
Journal:  Mucosal Immunol       Date:  2020-01-27       Impact factor: 7.313

Review 2.  Emerging Roles of Inflammasomes in Acute Pneumonia.

Authors:  Sangeetha Ravi Kumar; Sagar Paudel; Laxman Ghimire; Scott Bergeron; Shanshan Cai; Rachel L Zemans; Gregory P Downey; Samithamby Jeyaseelan
Journal:  Am J Respir Crit Care Med       Date:  2018-01-15       Impact factor: 21.405

3.  NLRP3 inflammasome is essential for the development of chronic obstructive pulmonary disease.

Authors:  Wenlin Yang; Hongyan Ni; Haifeng Wang; Huiling Gu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infection.

Authors:  Tyler A Rice; Todd A Brenner; Caroline M Percopo; Michelle Ma; Jesse D Keicher; Joseph B Domachowske; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2016-06-14       Impact factor: 5.970

Review 5.  Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria.

Authors:  Javier Oviedo-Boyso; Alejandro Bravo-Patiño; Víctor M Baizabal-Aguirre
Journal:  Mediators Inflamm       Date:  2014-12-01       Impact factor: 4.711

6.  Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens.

Authors:  Isidoro Martínez; Juan C Oliveros; Isabel Cuesta; Jorge de la Barrera; Vicente Ausina; Cristina Casals; Alba de Lorenzo; Ernesto García; Belén García-Fojeda; Junkal Garmendia; Mar González-Nicolau; Alicia Lacoma; Margarita Menéndez; David Moranta; Amelia Nieto; Juan Ortín; Alicia Pérez-González; Cristina Prat; Elisa Ramos-Sevillano; Verónica Regueiro; Ariel Rodriguez-Frandsen; Dolores Solís; José Yuste; José A Bengoechea; José A Melero
Journal:  Front Microbiol       Date:  2017-03-01       Impact factor: 5.640

7.  Inflammasome in the Pathogenesis of Pulmonary Diseases.

Authors:  Fengying Xu; Zongmei Wen; Xueying Shi; Jie Fan
Journal:  Exp Suppl       Date:  2018

8.  NLRP12 modulates host defense through IL-17A-CXCL1 axis.

Authors:  S Cai; S Batra; F Del Piero; S Jeyaseelan
Journal:  Mucosal Immunol       Date:  2015-09-09       Impact factor: 7.313

Review 9.  Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury.

Authors:  Vijay Kumar
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

Review 10.  [COPD: An early disease].

Authors:  V Margelidon-Cozzolino; K Chbini; N Freymond; G Devouassoux; A Belaaouaj; Y Pacheco
Journal:  Rev Pneumol Clin       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.